Alivus Life Sciences Ltd · NSE:ALIVUS
Alivus Life Sciences — Glenmark Life Sciences — Q4 FY24 Earnings Presentation
21 slides from Alivus Life Sciences's earnings presentation, Apr 25, 2024
Slide 1: Exchange filing cover letter
April 25, 2024 To, To, Dy. General Manager The Manager – Listing, Department of Corporate Services, National Stock Exchange of India Ltd., BSE Ltd., Plot No. C/1, G Block, P. J. Towers, Dalal Street, Bandra Kurla Complex, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Ref: Scrip Code: 543322 Re
Slide 2: Investor Presentation Q4 & FY24
Investor Presentation Q4 & FY24
Slide 3: Financial Performance Review
Financial Performance Review
Slide 4: FY24 Highlights
FY24 | Highlights “FY24 was a milestone year for Glenmark Life Sciences, marked by the successful acquisition by Nirma Limited. With Nirma's commitment and strategic vision, we are Dr. Yasir Rawjee poised for accelerated growth and market positioning. Managing Director & We concluded the financial y
Slide 5: Q4 & FY24 Performance
Q4 & FY24 Performance PAT Revenue EBITDA EBITDA PAT EPS (In ₹ Milli o n s) (In ₹ Milli o n s) (In ₹ Milli o n s) PAT Margin (In ₹) EBITDA Margin 23.6% 23.4% 33.7% 33.7% 19.9% 20.7% 30.4% 11.94 1,464 18.3% 6,213 29.0% 11.05 26.9% 1,355 2,093 9.69 9.69 1,188 1,187 1,950 5,954 1,742 1,725 5,785 5,728 Q
Slide 6: P&L Highlights | Q4 & FY24
P&L Highlights | Q4 & FY24 Particulars (In ₹ Millions) Q4 FY24 Q3 FY24 QoQ Q4 FY23 YoY FY24 FY23 YoY Revenue from Operations 5,366 5,728 -6.3% 6,213 -13.6% 22,832 21,612 5.6% Gross Profit 2,979 3,306 -9.9% 3,409 -12.6% 12,812 11,471 11.7% Gross Profit (%) 55.5% 57.7% 54.9% 56.1% 53.1% Other Income 3
Slide 7: Adjusted EBITDA | FY24
Adjusted EBITDA | FY24 Particulars (In ₹ Millions) FY24 FY23 EBITDA 6,863 6,712 One Time Bonus (Employee Cost) 375 - Transaction Cost (Other Expenses) 32 - Adjusted EBITDA 7,270 6,712 Adjusted EBITDA Margins 31.8% 31.1% 6
Slide 8: Healthy Returns Indicators
Healthy Returns Indicators ROICE Fixed Assets Turnover Working Capital Days 40% 202 166 36% 176 152 170 34% 3.3 3.4 31% 32% 2.9 2.9 98 102 107 99 89 152 136 120 116 122 -48 -43 -53 -59 FY20 FY21 FY22 FY23 FY24 FY20 FY21 FY22 FY23 FY24 -72 • ROICE is tracking at ~32% – Higher capital employed driven
Slide 9: Financial Performance Track Record
Financial Performance Track Record Robust growth and profitability indicators over the years Revenue EBITDA PAT EPS (In ₹ Milli o n s) (In ₹ Milli o n s) (In ₹ Milli o n s) (In ₹) EBITDA PAT EBITDA Margin PAT Margin 21.6% 20.6% CAGR 10.4.% 20.4% 31.5% 19.7% 30.6% 31.4% 31.1% 30.1% 22,832 18.6% 4,670
Slide 10: Business Performance Review
Business Performance Review
Slide 11: Segment Performance | Generic & CDMO business
Segment Performance | Generic & CDMO business CDMO Generic API (Rev enu e In ₹ Milli o n s ) (Rev enu e In ₹ Milli o n s) 568 5,428 5,299 464 5,105 355 5,042 4,846 253 Q4 FY23 Q1 FY24 Q2 FY24 Q3 FY24 Q4 FY24 Q4 FY23 Q1 FY24 Q2 FY24 Q3 FY24 Q4 FY24 • CDMO business witnessed a stable demand on • Gener
Slide 12: Segment Performance | GPL vs. External
Segment Performance | GPL vs. External External GPL GPL External (In ₹ Milli o n s) (In ₹ Milli o n s) % of Total Revenue % of Total Revenue 37.2% 33.5% 73.1% 33.9% 31.1% 2,309 26.9% 4,187 1,964 2,000 66.5% 62.8% 66.1% 68.9% 1,541 3,954 3,904 3,821 Q4 FY23 Q1 FY24 Q2 FY24 Q3 FY24 Q4 FY24 Q4 FY23 Q1
Slide 13: Market and Therapeutic Area Mix
Market and Therapeutic Area Mix Market Mix Therapeutic Area Mix 19% 22% 20% 19% 17% 34% 32% 31% 39% 38% 5% 6% Others 6% 3% 5% 6% 4% 5% Emerging 5% Pain Management Markets 4% 17% 15% 18% 11% Diabetes 83% 15% 81% 78% 80% 81% CNS Regulated Markets CVS 43% 43% 41% 36% 38% Q4 FY23 Q1 FY24 Q2 FY24 Q3 FY24
Slide 14: Company Overview
Company Overview LIFE SCIENCES
Slide 15: Global Footprint
Global Footprint • Filed 520 DMFs and CEPs across major markets; United States, Europe, Japan, Russia, Brazil, South Korea, Taiwan, Canada, China and Australia ROW 70+ 370+ 30+ 104 132 164 10+ 18 125+ 10+ 50+ 22 80 (Brazil) India – Mix of Regulated Number of Number of customers As of Mar 31, 2024 Re
Slide 16: R&D Capabilities
R&D Capabilities Cumulative Filing Status R&D Spend North (In ₹ Milli o n s) Therapy Europe Japan Brazil Australia ROW Total America R&D Spend CVS 38 33 4 21 10 35 141 As % to Sales CNS 38 25 8 13 2 17 103 Diabetes 10 5 - 8 - 13 36 3.3% Pain Management 1 2 - 4 1 9 17 3.0% Others 77 39 6 34 9 58 223
Slide 17: Quality-focused, compliant manufacturing & R&D infrastructure
Quality-focused, compliant manufacturing & R&D infrastructure Manufacturing Infrastructure R&D Infrastructure Annual Installed Last USFDA Mahape, Navi Mumbai Location Approvals Capacity Inspection Date R&D for new product development and complex USFDA, MHRA (UK), FIMEA molecules (Finland), Romania
Slide 18: Strategy Going Forward
Strategy Going Forward / LIFE SCIENCES
Slide 19: Strategic Growth Levers
Strategic Growth Levers 1 Gx API Business New product launches Geographical expansion Focus on new markets becoming more regulated New Growth levers 2 Pursue 2nd source opportunities with top generic players Ramp up CDMO portfolio Expand into complex API platforms Iron compounds Onco
Slide 20: Future Capacity Expansion Plan
Future Capacity Expansion Plan Operational Expansion Type Division Location Status & Planned Capacity Timelines 208 KL (Construction Completed) Q1 FY25 Brownfield API / Intermediate Ankleshwar Planned addition of 280KL-300KL FY25-FY26 18 KL (Construction Completed) Q1 FY25 Brownfield API Dahej Plann
Slide 21: Thank You
Thank You FOR FURTHER INFORMATION CONTACT Email: complianceofficer@glenmarklifesciences.com ERNST & YOUNG LLP – INVESTOR RELATIONS DIWAKAR PINGLE RUNJHUN JAIN Email: Diwakar.Pingle@in.ey.com Email: Runjhun.Jain1@in.ey.com CORPORATE OFFICE: REGISTERED OFFICE: T: 91 22 68297979 4th Floor, OIA House, 4
Glenmark Life Sciences — Q4 FY24 Earnings Presentation on 6ix